Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug
Graphical Abstract
Intravenous co-administration of siMcl1 and SAHA using pSTLOL could significantly inhibit the growth of tumor tissues.
Introduction
Although small interfering RNAs (siRNAs) are emerging as a new class of therapeutics, the development of effective delivery systems is critical if such molecules are to be useful as pharmaceuticals in various applications [1], [2]. Several siRNA clinical trials are in progress, treating localized ocular and lung disease [3]. A prime application of new siRNA therapy is anticancer therapeutics [4], [5]. To develop novel anticancer siRNAs, pharmacologically adequate amounts of siRNA must be delivered to tumor tissues, allowing knockdown of target genes/proteins.
Currently, anticancer siRNA delivery systems are under intense investigation [6]. Among various systems studied, cationic lipid-based systems have received a great deal of attention in efforts to provide the requisite silencing activity after local or systemic administration [7], [8]. Amino acids [9], synthetic chemicals [10], and peptides [11] have been conjugated to lipids to synthesize cationic molecules for siRNA delivery. Recently, combinatorial synthesis and screening of cationic lipids have been undertaken to develop new materials with improved delivery efficiency [12]. Although a great deal of progress has been made in this area, more effective siRNA delivery systems are required to reduce the expression of target genes after intravenous administration.
In the present study, we synthesized several oligolysine-based cationic lipid derivatives, and explored whether these materials could systemically silence target genes. Here, we report that trilysinoyl oleylamide (TLO)-based liposomal formulations reduced target gene expression after systemic administration. Moreover, we found that combined delivery of anticancer siRNA and an anticancer drug yielded synergistic anticancer activity.
Section snippets
Materials
Dioleyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE) were purchased from Avanti Polar Lipids (Birmingham, AL). Suberoylanilide hydroxamic acid (SAHA) was from Cayman Chemical (Ann Arbor, MI). Cholesterol (Chol) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Sigma-Aldrich (St. Louis, MO).
Preparation of cationic oligolysinoyl lipid-based liposomes
To prepare multilamellar liposomes, cationic oligolysinoyl lipids, DOPE, and Chol
Synthesis of cationic lipids
The synthesis schemes for the various cationic lipids are summarized in Suppl. Figs. 1 and 2. Oligolysinoyl oleylamides (OLO, Fig. 1A) were synthesized from oleylamine and various oligolysines with 1–10 lysine residues. Oligolysine peptides were covalently linked to oleylamine via formation of amide bonds between the amine groups (–NH2) of oleylamine and the carboxyl group (–COOH) of an oligolysine peptide (Suppl. Fig. 1). To synthesize trilysinoyl cationic lipids, the carboxyl group of a
Discussion
In the present study, we have shown that TLO-based cationic liposomes serve as an effective carrier for delivery of siRNA both in vitro and in vivo. Moreover, a combination of siRNA with the anticancer drug SAHA showed enhanced anticancer activity.
DOPE was used as the basic lipid component in the formulation of OLOL. DOPE is a fusogenic lipid, preferentially forming the inverted hexagonal phase typical of membrane fusion events [14]. The presence of DOPE in cationic liposomes enhances cellular
Acknowledgments
This work was supported by research grants from the Ministry of Education, Science and Technology (2010K-001245; 2010K-001356), from the Korean Health Technology R&D project, Ministry for Health, Welfare and Family Affairs (Grant No. A092010), and from the Bio-Green 21 program (Code No. 20100301-061-200-001-03-00), Rural Development Administration, South Korea.
References (34)
- et al.
siRNA delivery systems for cancer treatment
Adv. Drug Del. Rev.
(2009) - et al.
Anionic amino acid-derived cationic lipid for siRNA delivery
J. Control. Release
(2009) - et al.
DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA
J. Control. Release
(2010) - et al.
Octaarginine-modified multifunctional envelope-type nano device for siRNA
J. Control. Release
(2007) - et al.
The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route
J. Control. Release
(2005) - et al.
Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma
Mol. Ther.
(2006) - et al.
Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles
Biochim. Biophys. Acta
(1990) - et al.
Alpinia pricei rhizome extracts induce apoptosis of human carcinoma KB cells via a mitochondria-dependent apoptotic pathway
Food Chem. Toxicol.
(2008) - et al.
Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing
Biomaterials
(2010) - et al.
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412
Blood
(2007)
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
J. Biol. Chem.
Strategies for silencing human disease using RNA interference
Nat. Rev. Genet.
RNAi-based drug discovery and its application to therapeutics
IDrugs
Neovascular age-related macular degeneration: potential therapies
Drugs
Future prospect of RNA interference for cancer therapies
Curr. Drug Targets
Concepts in in vivo siRNA delivery for cancer therapy
J. Cell. Physiol.
Lipid-based nanotherapeutics for siRNA delivery
J. Intern. Med.
Cited by (91)
Vesicular drug delivery systems: a novel approach in current nanomedicine
2023, Molecular Pharmaceutics and Nano Drug Delivery: Fundamentals and ChallengesDelivery of small interfering RNAs by nanovesicles for cancer therapy
2022, Drug Metabolism and PharmacokineticsOvercoming barriers by local drug delivery with liposomes
2021, Advanced Drug Delivery ReviewsCitation Excerpt :When using intravenous injection, the same LIPs were found to reduce tumor growth (compared to control formulations) only when siRNA together with an anticancer drug (suberoylanilide hydroxamic acid) were co-encapsulated [90], proving the advantage of the IT route. Summarizing this part, it is proven from numerous recent studies that when possible, direct IT injection of LIP therapeutics is an effective and safe method for treatment of cancer [75–90]. The use of ligand-targeted-LIPs or other types of trigger-sensitive LIPs (temperature or pH sensitive), as well as hybrid LIPs embedded in gels (for enhanced retention at the injection site) is particularly interesting for the delivery of oligonucleotide and/or conventional therapeutics by IT injection.
Delivery systems for vorinostat in cancer treatment: An updated review
2021, Journal of Drug Delivery Science and TechnologypH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel
2021, Materials Science and Engineering CStaphylococcus aureus-mimetic control of antibody orientation on nanoparticles
2019, Nanomedicine: Nanotechnology, Biology, and MedicineCitation Excerpt :The zeta potential values can be modified by adjusting the molar composition of negatively charged nanoparticles. Although we used negatively charged nanoparticles tagged with anti-HER2 antibody, it would be possible to formulated positively charged nanoparticles by replacing PG with cationic lipids.24,25 The antibody-tagged cationic nanoparticles may have applications for delivery of nucleic acid therapeutics.26,27
- 1
Both authors contributed equally to this manuscript.